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Abstract
Background: In attempting to formulate potential WHO guidelines for the diagnosis 
of male infertility, the Evidence Synthesis Group noted a paucity of high-quality data 
on which to base key recommendations. As a result, a number of authors suggested 
that key areas of research/evidence gaps should be identified, so that appropriate 
funding and policy actions could be undertaken to help address key questions.
Objectives: The overall objective of this Consensus workshop was to clarify current 
knowledge and deficits in clinical laboratory andrology, so that clear paths for future 
development could be navigated.
Materials and Methods: Following a detailed literature review, each author, prior 
to the face-to-face meeting, prepared a summary of their topic and submitted a 
PowerPoint presentation. The topics covered were (a) Diagnostic testing in male 
fertility and infertility, (b) Male fertility/infertility in the modern world, (c) Clinical 
management of male infertility, and (d) The overuse of ICSI. At the meeting in Cairo 
on February 18, 2019, the evidence was presented and discussed and a series of 
consensus points agreed.
Results: The paper presents a background and summary of the evidence relating to 
these four topics and addresses key points of significance. Following discussion of 
the evidence, a total of 36 consensus points were agreed.
Discussion: The Discussion section presents areas where there was further debate 
and key areas that were highlighted during the day.
Conclusion: The consensus points provide clear statements of evidence gaps and/
or potential future research areas/topics. Appropriate funding streams addressing 
these can be prioritized and consequently, in the short and medium term, answers 
provided. By using this strategic approach, andrology can make the rapid progress 
necessary to address key scientific, clinical, and societal challenges that face our dis-
cipline now and in the near future.
K E Y W O R D S
environmental influences, epigenetics, fertility, genetics, ICSI, male reproductive health, 
semen analysis, sperm DNA
2  |     CONSENSUS WORKSHOP GROUP
1  | BACKGROUND TO THE CONSENSUS 
DOCUMENT
The Evidence Synthesis Group formulating potential World 
Health Organization (WHO) guidelines for the diagnosis of 
male infertility noted a paucity of high-quality data on which to 
base key recommendations.1 Remarkably, even with basic ques-
tions, there was not sufficient data to formulate ‘low’, much less 
‘strong’, recommendations. Moreover, fundamental deficien-
cies were evident regarding long-standing questions. Overall, 
this was deemed symptomatic of a much broader ‘andrological 
ignorance’.1,2
Suffice it to say that there is a fundamental lack of knowl-
edge that substantially obstructs research, diagnosis, and patient 
management. Yet, paradoxically male infertility is a part of a dy-
namic and growing health industry within which ART is a highly 
innovative, billion-dollar enterprise. Reproductive medicine rap-
idly attracts the attention of the general public and, as such, the 
perception is that significant progress has been made. This is an 
illusion as, for example, numerous basic, clinical, and scientific 
questions in andrology have remained unanswered—some for over 
50 years.2,4
Following the first birth of an ICSI-conceived child in 1992, use 
of ICSI worldwide has increased dramatically and the treatment 
is increasingly used even when no male problem is present.5,6 But 
ICSI treatment is paradoxical: ICSI does not treat male fertility as 
the man's fertility status remains unchanged (only the gametes are 
manipulated), and the woman largely carries the treatment burden 
for male infertility. Furthermore, and ironically, many authors argue 
that the success of ICSI has focused research onto the female (to 
optimize the ART process) and thus diverted attention away from 
identifying the causes and thus rational diagnosis and treatment of 
male infertility.7
Recently, we detailed how this parlous situation was reached 
and suggested how we might move forward in a structured way 
to improve our understanding and management of male repro-
ductive health issues.2 One component of this was to suggest an 
analysis of the underlying deficits in our knowledge of clinical lab-
oratory andrology and to identify strategies whereby medical and 
scientific research might seek to fill these gaps. In so doing, we 
can start to build a sound foundation for the future of andrology 
as a biomedical specialty: a future in which the male partner in 
infertile couples is seen as a patient and not merely a source of 
spermatozoa, in which there are effective first-line treatments for 
male factor infertility and in which political leaders understand 
how poor product regulation and neglect and mismanagement 
of our environment are impacting human fertility, and health in 
general.
The overall aim of this Consensus workshop (see Table 1 for 
details of participants) was to clarify the current deficits in knowl-
edge so that clear paths for future development could be navigated. 
Following presentation of the evidence a total of 36 consensus 
points are presented.
2  | WORKSHOP SESSION 1—DIAGNOSTIC 
TESTING IN MALE FERTILIT Y/INFERTILIT Y
2.1 | Semen analysis, standardization, and reference 
ranges
2.1.1 | Origins of standardization in semen analysis
Although the semen sample examined in the laboratory differs sig-
nificantly to the situation in vivo, it is the standard approach to as-
sessment of male infertility. The first protocol for analysis of human 
semen that could be considered as suitable for clinical laboratory 
testing came from Macomber & Sanders.8 These investigators di-
luted a known volume of semen with a known volume of bicarbo-
nate/formalin solution to ‘dissolve’ seminal mucus and formalin to 
‘stop the activity’ of the spermatozoa. After mixing, an aliquot was 
placed in a blood counting chamber (hemocytometer) allowing cal-
culation of the sperm concentration. They commented on sources of 
error in the technique and how to proceed when the sperm numbers 
were either very high or very low and concluded that ‘the spermato-
zoa count has proved a useful guide to fertility’.
In the early 1950s, a series of investigations on human semen 
quality were published that can arguably be credited with heralding 
modern andrology.9 Throughout these investigations, close atten-
tion was paid to minimizing confounding variables. For example, the 
method for counting spermatozoa (hemocytometer) was standard-
ized and a single, gold standard observer (the principal investigator) 
examined initial motility and counted all specimens. Semen samples 
from 1000 men of known fertility and 1000 men from infertile mar-
riages were evaluated, and purportedly, it was the results from this 
report that served as the basis for the reference ranges in the first 
WHO supported Laboratory Manual for the Examination of Human 
Semen.10 Since 1980, the WHO has published four revised editions 
of the manual containing standardized methods for examining and 
testing semen (WHO 1987, 1992, 1999, 2010) in an attempt to align 
the discipline more closely with other standardized clinical labora-
tory practices.
2.1.2 | WHO (2010) reference values and their 
impact on clinical and laboratory practice
Strict adherence, by multiple laboratories, to standardized methods 
for semen testing and evaluation makes data more easily comparable 
and analysis more statistically powerful, such that ranges of ‘refer-
ence’ values can be derived. The 2010 WHO manual was the first to 
contain reference values derived from a large set of data.12 However, 
a limitation was their derivation from a limited demographic (Europe, 
Australia, and United States) and, in addition, there was variation in 
methods used for assessing critical semen parameters.
Ideally, information provided by the WHO should facilitate 
meaningful interpretation of semen analysis data and conclusions 
about fecundity both for populations and individual patients. In the 
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2010 WHO manual, the reference ranges were based on results 
from relatively few fertile men (428-1941) whose partners had a time 
to pregnancy of 12 months or less.12 When reference ranges are cal-
culated in clinical chemistry, it is common to include 95% of obtained 
data and, usually, the 2.5th and 97.5th centiles form the lower and 
upper reference limits. The rationale is that both too high and too 
low values may be considered harmful. However, as high values for 
semen parameters usually are not considered to impair fertility, the 
WHO guidelines use a one-tailed approach, basing the reference 
levels on the 5.0th centiles.13 WHO emphasizes that ‘Men whose 
semen characteristics fall below the lower limits given are not nec-
essarily infertile’. However, it cannot be concluded that a man will 
have a normal fertility chance if his semen parameters are above the 
reference ranges. Several studies have shown that fertilizing abil-
ity diminishes if the sperm concentration is below 40-50 million/ml, 
total sperm count below 140-150 million, the percentage of motile 
spermatozoa below 70%, and percentage of morphologically normal 
spermatozoa below 9%-12%.14-16 These values, which considerably 
exceed the WHO reference levels (15 million/ml, 39 million, 40%, 
and 4%, respectively), indicate levels at which ability to conceive 
may become impaired. It is probable that, in the future, subcatego-
ries will need to be introduced to take account of this complexity. 
Additionally, semen quality must be considered as a continuum and 
models to predict fertility chances, rather than specific reference 
levels, must to be developed. Such models should also take into ac-
count the potential interaction between the different semen param-
eters. It is obvious that data obtained from fertile men are relevant 
to guide us to understand the impact of semen quality. However, 
adding information from well-defined populations of men with fer-
tility problems may also be relevant to calculation of risk estimates 
for prolonged waiting time to pregnancies as would, for example, 
accounting for factors such as female factor and variation between 
ejaculates.17
Unfortunately, the WHO13 reference values are often wrongly 
equated with indicating fertility if a sample exceeds all lower reference 
limits and infertile if it falls below the reference for one or more param-
eters. A consequence of using reference values as cut-offs is that, as 
new data emerge and reference values are refined, semen samples may 
change classification.18,19 Importantly, it is critical not to use one single 
semen parameter as a marker of male reproductive potential. Guzick et 
al15 formulated three categories: subfertile, fertile, and ‘indeterminate’. 
Odds ratios for infertility climbed dramatically from the combination of 
all ‘fertile’ combined sperm parameters (OR 1.0) to all subfertile sperm 
parameters (OR ~ 16). Sperm parameters in mixed combination had 
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escalating odds ratios for infertility. The take home message was that 
significantly greater diagnostic ability comes when the sperm parame-
ter assessments are combined rather than used individually.1
2.1.3 | Compliance and quality
To determine whether semen assessments are robust throughout 
the world requires that there are standardized methods used by clin-
ical and research laboratories. Such standardized methods certainly 
exist but a wealth of data shows that semen assessments, for a vari-
ety of reasons such as lack of adherence to methods, can have poor 
reproducibility.1,20-22 As a result, a patient categorized as subfertile 
in one laboratory has reasonable likelihood of being categorized as 
fertile in another laboratory and vice versa.
One potential way to correct for lack of standardization is by of-
fering specialized training courses,24,25 Statistical comparison of par-
ticipant pre-training to post-training results clearly demonstrates a 
significant improvement. However, training must be supported by 
routine external quality assessment (EQA). EQA not only provides a 
mechanism for assessing testing proficiency of personnel but also com-
pliance with standardized methods for testing. For example, a survey 
was conducted of andrology workshop-trained and workshop-certi-
fied staff and of non-certified laboratory staff working in Polish labora-
tories to assess compliance with WHO (2010) standards.26 Regardless 
of certified training or not, there was an appreciable lack of compliance 
with, and adherence to, WHO standards. In Italy, an analogous study 
was conducted in which technologists participated in three trials of 
EQA assessment. The results from this study showed a high degree of 
variation in methodology and proficiency, and this in spite of the fact 
that a training session was provided between trials 2 and 3.27
Clearly, a greater unified effort toward continuous training and 
compliance to improve the standard and consistency of semen analysis 
is required. The beneficial effects of such compliance and adherence to 
standards are illustrated by the data of Punjabi who evaluated 15 years 
of results (1997-2012) from a voluntary EQA program in Belgium.28 
Results showed that adoption by laboratories of the Neubauer 
hemocytometer as the standard sperm counting chamber resulted 
in a decrease in CV compared with other chambers used. This study 
demonstrates that long-term ‘buy-in’ by administration and laboratory 
staff to published professional standards leads to success.
2.2 | The current and future potential of sperm 
functional testing
To fertilize, a spermatozoon must penetrate cervical mucus, pass 
through the uterus, enter the oviduct, and ascend to the site of 
fertilization (which probably involves binding to and active escape 
from the lining cells), locate the oocyte, undergo acrosome reaction, 
penetrate the cumulus and zona, and fuse with the oocyte, forming 
the sperm aster and achieving syngamy.30 These different aspects 
of the spermatozoon's activity involve a wide variety of functional 
attributes, impairment of any of which might underlie a failure to 
fertilize. Tests of sperm attributes/fertilizing ability therefore ad-
dress a wide range of functional characteristics, for example, motil-
ity/hyperactivation assessment, mucus penetration, zona pellucida 
interaction, acrosome reaction, and oocyte penetration. In addi-
tion, biochemical assays and marker assays such as localization of 
membrane constituents (see below) can be used to assess charac-
teristics believed to be correlated with sperm function. Such tests 
will address one or more of these key functional attributes and aim 
to identify samples where a particular attribute (or attributes) are 
impaired. Since the etiology of male infertility/subfertility can vary 
(both the functional defect(s) and the causative lesion(s)), such tests 
could detect subfertility related to a group of lesions with a common 
functional effect, but might nevertheless detect only a small subset 
of potential fertility-compromising defects.
It is remarkable that little progress has been made on true sperm 
function tests since the 1980s/1990s.31,32 Some, for example, acro-
some reaction (AR) and zona binding are reported to have potential 
clinical value but the literature is not consistent (eg, questioning of 
both sensitivity and specificity in a recent meta-analysis.33 Use of 
these tests often requires access to human biological material (zonae, 
cervical mucus) and involves complex manipulation requiring high 
levels of operator training. Moreover, biochemical assays often re-
quire technologies that are relatively expensive (eg, flow cytometry, 
fluorescence plate reader) and/or low throughput. Computer-aided 
sperm analysis (CASA) is potentially valuable but is also expensive 
to set up, requires training and is yet to be fully adopted in androl-
ogy laboratories.34 Improvements in technology and development 
of standardized applications might improve this. To date, CASA has 
been used primarily for descriptive analysis but the development of 
functional assays (such as assessment of hyperactivation in capaci-
tating or agonist-stimulated cells) should be an aim.34,35 Despite this 
overall lack of progress, there are a number of areas where recent 
advances suggest that progress in the development and application 
of new sperm functional tests could occur. These include proteom-
ics of spermatozoa and the seminal plasma,36 metabolomics and mi-
tochondrial metabolism,37-39 novel markers of fertilizing ability, for 
example, the Cap test40 and the considerable progress being made 
in understanding of sperm physiology and cell signaling, particularly 
the expression and functions of spermatozoon ion channels. For il-
lustrative purposes, some examples are briefly considered below.
Mitochondrial status of live spermatozoa can be assessed using 
fluorescent dyes such as JC-1, either in single cells (by microscopy) 
or in populations (flow cytometry41). Measurements made with JC-1 
and other dyes have shown that mitochondrial membrane potential 
is correlated with markers of semen quality such as motility, viability, 
count, and morphology42,43 but diagnostic/predictive value for fer-
tilizing potential has not been established.
The Cap-score assay is based up the relationship between local-
ization of the ganglioside monosialotetrahexosylganglioside (GM1) 
and capacitation status. Spermatozoa which can undergo acrosome 
reaction are drawn from a subpopulation that display a ‘capaci-
tated’ GM-1 pattern where the ganglioside is localized apically.44 
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The staining procedure is carried out on fixed cells so samples can 
be sent to a central laboratory allowing standardization. In a recent 
study, where men likely to have trouble conceiving were identified 
using their Cap-score, the absolute pregnancy rate was almost three 
times higher in these men considered likely to conceive according to 
the previously defined Cap-Score reference ranges.40 However, the 
data are still preliminary and more clinical trials are required.
Krausz et al45,46 first showed that the ability of progesterone to 
induce an immediate Ca2+-influx in human spermatozoa is correlated 
with fertilization rate at IVF. This action of progesterone is now 
known to reflect activation of CatSper, the primary Ca2+ channel 
of spermatozoa. Recent work has confirmed this finding and shown 
similar correlations with other agonists47,48 but no attempt has yet 
been made to identify a predictive value (level of response below 
which fertilization failure is predicted). Men with no detectable 
[Ca2+]i response to progesterone (indicating no functioning CatSper) 
appear to be unable to fertilize naturally or by IVF and thus require 
ICSI, but extensive screening suggests that this condition is very 
rare, probably being less than 1% of IVF patients.45-47,49 A more com-
mon defect in spermatozoon ion channel function might be in reg-
ulation of plasma membrane potential (Vm). Brown and colleagues, 
using patch clamping to measure K+ currents and estimate Vm, found 
that in > 10% of samples from IVF patients the membrane potential 
was abnormally depolarized and that a highly depolarized membrane 
potential (Vm ≥ 0 mV) may be associated with low fertilization rate.
50
These and other new assays are potentially of considerable 
value, though in almost all cases the clinical value is yet to be as-
sessed in large groups of patients. With regard to use in the clinic, 
the most useful tests will probably be prediction of IUI/IVF/ICSI 
failure although these are clearly different biological endpoints.51,52 
Two areas of rapid progress provide grounds for guarded optimism: 
(a) real progress in our understanding of sperm physiology (and con-
sequent identification of new parameters for assay) and (b) improve-
ment of high-throughput assay techniques, including simultaneous 
flow cytometry/fluorescent imaging. Development of multiplex 
tests for several sperm attributes, based on flow cytometry or plate 
reader methods (eg, simultaneous detection of Cap-1 pattern, AR, 
CatSper expression, mitochondrial Vm), may enable more reliable 
assessment of sperm functional competence and probability of fer-
tilization failure, facilitating selection of the most appropriate treat-
ment pathway.
2.3 | Sperm DNA assessment
As sperm DNA fragmentation (sDF) is only partially related to semen 
quality, it could be an important addition to the sperm function test-
ing armamentarium.53,54 However, there is currently debate regard-
ing its routine use as part of the work-up in cases of male and couple 
infertility.55 The most important issue emerging from this debate is 
the presence of several possible assays, many of them not stand-
ardized. These assays vary greatly both in the method and type of 
damage they are detecting. The type of damage assessed by the 
different techniques is critical. Indeed, there is evidence that the 
indirect methods (Sperm Chromatin Structure Assay [SCSA] and 
sperm chromatin dispersion test [SCD; also known as Halosperm 
test] detect the susceptibility of chromatin to undergo DNA damage 
and fragmentation, whereas more direct methods (TUNEL [terminal 
deoxynucleotidyl transferase dUTP nick end labeling] and Comet 
[single cell gel electrophoresis assay] actually assess the presence of 
breaks within the DNA.
As the most important damage is that which affects reproduc-
tive outcomes, it is important to clearly define the relationship be-
tween the test used and the clinical outcome. This point has been 
addressed in recent meta-analyses56-61 where studies were grouped 
according to the different methods of assessment. When the miscar-
riage rate was considered as the endpoint, both after ARTs and natu-
ral pregnancies, the TUNEL method appeared to be the most useful, 
followed by SCSA.59 A more recent meta-analysis, considering cou-
ples with repeated pregnancy loss (RPL) following natural concep-
tion, revealed a similar, significant association both when TUNEL 
and SCD were used to evaluate sDF.61 McQueen et al57 who also 
presented a systematic review and meta-analysis of RPL concluded 
that TUNEL was the most appropriate sDF method. The meta-anal-
ysis by Osman, where the endpoint was live birth rate after ARTs, 
suggested that TUNEL was the most clinically useful technique fol-
lowed by Comet.58 Cissen et al56 who considered clinical pregnancy 
after IVF and ICSI as the endpoint, showed only TUNEL and Comet 
to be of ‘fair discriminatory capacity’, whereas SCSA and SCD tests 
showed a ‘poor predictive capacity’. Finally, Simon et al60 reported 
that TUNEL, Comet, and SCD were predictive of clinical pregnancy 
after IVF and ICSI, with SCD being the least significant. Although 
the studies included in these meta-analyses differ considerably, and 
the female factor is often neglected, they report evidence that SCSA 
and SCD have limited clinical value. Overall, these studies confirm 
that the different techniques detect different types of damage.
The above conclusion is also supported by studies investigat-
ing the effect of sperm selection techniques on DNA integrity. For 
example, density gradient centrifugation (DGC) may provoke an in-
crease of DNA damage in highly motile selected spermatozoa.62-64 
However, in contrast to assessment using TUNEL, such an increase 
in DNA damage does not appear to be detected by SCSA.62 Further 
studies will be necessary to understand whether Comet and SCD are 
also able to detect DNA damage after DGC. The scenario appears 
different in studies on natural conception65 and intrauterine insem-
ination (IUI),66 where SCSA results were found to be a reasonable 
predictor of pregnancy. However, overall, there is an urgent need for 
more primary data in this arena as meta-analyses are only as strong 
as the original data available.
Another key challenge is that several different sDF threshold val-
ues have been proposed for discriminating between pathological and 
normal conditions. This inconsistency further contributes to the cur-
rent confusion. At present, the only possibility is for each laboratory 
using sDF to set its own cut-off value, suitable for use with the estab-
lished method, for distinguishing between fertile and subfertile or in-
fertile men. It is anticipated that, once further high-quality clinical data 
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are available, consensus guidelines can be developed to identify the 
gold standard method(s) to evaluate sDF for couple infertility work-up.
Emerging data in the literature suggest that several conditions 
are associated with high SDF levels including varicocoele, unex-
plained infertility, recurrent IVF or ICSI failure, advanced age, dia-
betes, and presence of inflammatory signs of the lower genital tract 
and cancer.67,68 Patients with these conditions might benefit from 
evaluation of SDF as diagnostic tool but, with the possible exception 
of varicocelectomy, effective treatments for diagnosed SDF remain 
to be determined.
In conclusion, we are still some way from understanding how 
best to introduce the assessment of SDF into the male infertility 
work-up. At least three important areas remain: (a) establishing the 
gold standard technique(s) for each reproductive outcome; (b) finding 
effective pharmacological treatments to decrease clinically relevant 
sperm DNA damage in vivo; and (c) establishing correct strategies to 
prepare spermatozoa for ARTs to avoid iatrogenic damage. Suffice it 
to say, there is a need for large-scale, robust, controlled trials on the 
value of sDF testing.
3  | WORKSHOP SESSION 2:  MALE 
FERTILIT Y/INFERTILIT Y IN THE MODERN 
WORLD
The study by Carlsen suggesting that human sperm counts were in 
the process of significant decline,69 stimulated great interest while 
precipitating a lively and ongoing debate about the nature of the 
data analyzed and whether the interpretation was sound. Data ana-
lyzed in subsequent studies appear to confirm that this downward 
trend is real, at least in men of western countries (70; see below), and 
much of the debate is now moving on to questions of underlying 
causes and mechanism(s).
3.1 | Is male fertility really declining?
3.1.1 | Temporal trends in semen quality
Meta-analyses show a negative time trend in semen quality
Although a temporal trend in semen quality was discussed briefly 
in the 1970s,71,72 the current ongoing debate was started in 1992 
by an analysis of semen quality data from 61 studies published 
between 1938 and 1990.69 The authors concluded that there was 
‘Evidence for decreasing quality of semen during past 50 years’. A 
re-analysis by Swan et al, which included data from a further 47 
studies, corroborated the finding.73 In 2017, the most comprehen-
sive meta-analysis to date was published,70 incorporating 244 es-
timates of sperm concentration and total sperm counts, based on 
185 studies (including studies on general [unselected] populations 
and on selected fertile men of 42 935 men who provided semen 
samples between 1973 and 2011. Criteria for inclusion of stud-
ies covered semen collection methods, assessment methods, and 
statistical analysis. Data analysis took account of age, ejaculation 
abstinence period, and number of samples from each man. Trends 
did not differ among studies from Europe/Australia and America 
so these areas were combined into one group of Western men. 
The observed trends were dependent on the population group, 
the largest decline in semen quality being among the Western 
unselected men where there was a 1.4%/year decrease in sperm 
concentration (−1.38 million/ml/year; confidence interval −2.02 to 
−0.74 and 1.6%/year decrease in total sperm count (5.33 million/
year; confidence interval −7.56 to –3.11. A less pronounced de-
crease was detected among the Western fertile men (sperm con-
centration −0.68 million/ml; confidence interval −1.31 to −0.05 
and total sperm count (2.12 million/ml; confidence interval −4.31 
to 0.07. When the analysis was restricted to data collected after 
1995, the slopes were slightly steeper than for the entire period 
from 1973, arguing against an attenuation of the adverse trends. 
No conclusions could be reached about men from Non-Western 
countries primarily because few studies conducted in these areas 
have been carried out/reported.
Year of birth may be an important factor
Following the Carlsen publication in 1992, other research groups 
started to evaluate or re-evaluate data they had previously col-
lected. Examination of 1351 fertile semen donor candidates 
from Paris during a 20-year period showed a decrease in mean 
sperm concentration from 89 million/ml in 1973 to 60 million/ml 
in 1992.74 After adjustment for age and abstinence period, each 
successive calendar year of birth was associated with a 2.6% de-
crease in mean sperm concentration pointing to a birth cohort ef-
fect stronger than the effect of the year of examination (−2.1%). 
Furthermore, sperm motility and morphology were negatively 
associated with calendar year and year of birth, whereas semen 
volume was not. This study also showed the importance of ac-
counting for confounders, since greater age was associated with 
a decreased sperm concentration, percentage of motile sperma-
tozoa, and percentage of morphologically normal spermatozoa, 
and ejaculation abstinence period was positively associated with 
sperm concentration and negatively with sperm motility. A sub-
sequent Scottish study, investigating semen donor candidates 
and not restricted to men with proven fertility, similarly showed 
deterioration of semen quality as a consequence of later year of 
birth.75 A study published in 2012 confirmed the decrease in a 
population of French fertile donors over a 34-year calendar pe-
riod, total sperm counts had decreased from 443 to 300 million, 
without any concomitant change in semen volume.76 Studies of 
university students from the southern part of Spain, born between 
1974 and 1993, have also shown a decrease in both sperm concen-
tration and total sperm count according to year of birth.77
In contrast to the studies described above, no trends among 
Swedish or Danish men from the general populations have been de-
tected during the last 20 years. The Swedish study compared results 
from men investigated in 2000-2001 and in 2008-2010 and did not 
detect any difference between these two time points.78 Similarly, no 
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changes were detected among Danish men in the period between 
1996 and 2016.79 However, in a comparison with a historical Danish 
cohort examined in 1940-1943, where sperm concentration was as-
sessed by the same type of haemocytometer as used in the studies 
1996 to 2016, it was shown that recent sperm counts were consid-
erably lower. Sperm concentration had decreased from a median 
above 60–45 million/ml and total sperm count from more than 300 
to 143 million.80 Vierula et al81 reported that sperm count of Finnish 
men was high and unchanged. However, subsequent prospective 
cohort studies of young men from the general population from 
south-western Finland detected a decreasing sperm count among 
men born in the period 1979-1987.82 Due to the relatively short du-
ration of the investigation and the age of the men, it was not possible 
to determine whether these changes were best described according 
to year of birth or year of investigation (1996-2006). In a further in-
vestigation of new cohorts of Finnish men, a continued decrease has 
recently been reported.83
As stated above, the meta-analysis by70 also reported findings 
for other populations in addition to Western men but did not find 
any significant declines for studies from South America, Asia, and 
Africa. This lack of significant findings from non-Western countries 
may partly be accounted for by limited statistical power and the ab-
sence of studies in unselected men in these non-Western countries 
prior to 1985.70 The main obstacle to using many historical publica-
tions is that many clinical studies on semen quality have dealt with 
selected groups of men like volunteers enrolled after advertisement, 
candidates for vasectomy or infertility patients, which hampers in-
terpretation. Since publication of the Carlsen paper in 1992, there 
have numerous publications based on such populations reporting a 
downward trend in semen quality and it is beyond the scope of this 
paper to summarize all. Following the Levine publication in 2017, 
a meta-analysis of African data from 2017 concluded that there is 
‘Evidence for decreasing sperm count in African population from 
1965 to 2015’ based on mixed populations from infertility clinics, 
laboratory studies, and cohort studies.84 This conclusion may be 
true but due to the potential selection biases, the overall pattern 
in African men still remains unclear. A study of Indian fertile men 
detected a small downward trend in sperm concentration during a 
37-year period and a steeper decline among infertile men. The selec-
tion bias for the infertile men was not described, and the methods 
for assessment of semen parameters were not discussed.85 Studies 
from China investigating semen donor candidates where selection 
biases may be similar over the years have recently been published 
and described a downward trend for sperm concentrations and mo-
tility.86-88 A minor disadvantage is that assessments were done using 
Makler chambers which may lead to a lower precision in determina-
tion of semen variable,89 but it provides some evidence that there 
may also have been a recent change in semen quality among men 
from various regions in China.
Conclusions about semen quality based on retrospective data
Although the retrospective approaches as described above are not 
ideal, this should not prevent us from trying to learn about the past. 
The existing analysis of historical data is the best that can be done, 
and the results clearly point to adverse temporal trends in semen 
quality and thereby in a broader sense in male reproductive health, 
at least among Western men. Interestingly, the association between 
year of birth and change in semen quality suggests that we should 
look for reasons among pre-natal events affecting testicular develop-
ment.90 This does not exclude the potential importance of post-natal 
events.91,92 It is interesting to note that in most Western countries, 
there have also been increases in incidence of testis cancer concom-
itantly with the decrease in semen quality.93 These increases also 
seem to be more strongly related to the year of birth than the actual 
calendar year the cancer appears, with a highest incidence among 
Danish and Norwegian men who apparently also have the lowest 
sperm counts.94 Imperfect as they are, these retrospective studies 
are strong enough to warn us about a current problem and inspire us 
to establish well-designed studies that can be used not only for lon-
gitudinal future measures but also to describe the current situation 
and potential reasons for declining semen quality.
3.1.2 | Studies designed to detect between-country 
differences, current situation, and future trends in 
semen quality
Inspired by these temporal trends in semen quality, cross-sectional, 
standardized, and coordinated studies have been designed and un-
dertaken to investigate semen quality of men from the general pop-
ulation (unselected regarding fertility status) in primarily western 
Europe, the United States, and Japan.94-99 Similarly, standardized and 
coordinated studies of fertile men have also been undertaken.100-102 
When successfully carried out, such studies will contribute more 
conclusive information about the existence of differences in semen 
quality between countries than can be achieved by additional analy-
ses of previously collected data. Furthermore, besides being able 
to describe the current situation, these data will serve as reference 
points for future follow-up studies to detect temporal changes and 
might also provide indications for the cause(s) of declining semen 
quality.
Selection bias is important to consider when studies are designed
A description of semen quality in a population must rely on results 
from examinations of a sample of men because it is not possible to 
examine the entire population. Therefore, since the aim must be to 
have a representative sample, an important question to consider is 
whether selection bias might influence outcome.103 Clearly, selec-
tion bias cannot completely be avoided and it is therefore essential 
that basic variables describing fertility status, health status, lifestyle 
factors, and educational status are included and analyzed in cross-
sectional semen quality studies.104
Concern about fecundity of men from general populations
Standardized studies of men from the general populations of 
Western countries (see above) have shown statistically significant 
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differences in average semen quality levels between men from dif-
ferent countries. From a biological point of view, these between-
country differences are less pronounced than the within-country 
differences between men from the general population and men of 
proven fertility. When these studies are interpreted according to the 
association between semen quality and likelihood to obtain preg-
nancy,14-16 rather than the artificial binary reference levels provided 
by the WHO (WHO 2010, see above discussion), they might indicate 
that some men from general populations have semen quality that 
raises concern for their fecundity.93,105,106 However, these predic-
tions remain to be rigorously tested.
3.2 | Semen quality is not only a marker of 
fecundity but also health
Recently, it was indicated that impaired semen quality/male infer-
tility is associated with shorter life expectancy and increased long-
term morbidity.107-110 The mechanisms underlying this association 
are not clearly understood, but reduced semen quality seems to 
be a marker that is linked to mortality in a dose-dependent man-
ner and also to morbidity. For example, in a Danish population of 
men from infertile couples, men with a sperm concentration of 
195-200 million/ml were, on average, hospitalized for the first time 
7 years later than men with a sperm concentration of 0-5 million/
ml.110 Impaired semen quality has been linked to a higher risk of 
testicular cancer in the years following infertility evaluation, both 
among Danish and US men,111 and some studies have suggested 
a link with development of prostate cancer, although this has not 
been confirmed by all studies.68,112,113 Other malignancies such 
as melanoma, bladder, thyroid, and hematological cancers have 
also been more frequently observed among infertile men.67,68 
Significant associations between diabetes mellitus, metabolic dis-
orders, and male infertility were found, and infertile men seem 
to have a higher risk of developing cardiovascular diseases.107,114 
However, incidence of these diseases is not sufficient to explain 
the observed association between semen quality and mortality.109 
Although it is still not understood which diseases are associated 
with impaired semen quality, it seems that fertility and especially 
impaired semen quality might represent a universal biomarker of 
later health and survival.
Infertility may hence serve as a marker of serious conditions 
later in life, but this association is in most cases not understood. It 
has been suggested that adverse lifestyle or environmental expo-
sure during early fetal life, combined with a genetic or epigenetic 
predisposition, may lead to impairment of reproductive function and 
endocrine imbalance, which in turn may lead to cancer, osteoporosis, 
metabolic, and cardiovascular disease. However, the association be-
tween fertility and health later in life may also be confounded by cur-
rent health and lifestyle factors. For example, obesity and smoking 
are known not only to hamper fertility, but also the general health 
and life expectancy are negatively affected.115,116 However, despite 
the well-known adverse effects of such factors, they do not explain 
the overall associations between semen quality and morbidity.117 
Most men presenting with low semen quality have normal serum 
testosterone (T) levels,118 and for most, the hormonal profile does 
not indicate immediate need of androgen replacement therapy, but 
rather suggests that the capacity of the testicular Leydig cells to pro-
duce testosterone is decreased. Recently, a compensated reduction 
in Leydig cell function—assessed as a decreased ratio between tes-
tosterone and luteinizing hormone (T/LH)—has been described even 
in men with semen quality well within the WHO normal reference 
ranges.119 Most cases of testosterone deficiency develop through 
an initial stage of compensated Leydig cell failure,120 and most likely, 
Leydig cell function decreases with age.121 However, it remains to 
be investigated whether men with subtle Leydig cell failure at young 
age will develop clinical symptoms of Leydig cell failure at a later 
stage. Thus, it is currently unresolved to which degree Leydig cell 
failure contributes as a causative factor to the associations between 
semen quality and health.
Men with fertility problems represent a relatively large and easily 
reachable part of the population showing excess mortality and mor-
bidity risk. Therefore, men seeking help for infertility could be a good 
target for preventive measures aimed to achieve ‘healthy aging’. As 
recognition of this association has only recently emerged, the nature 
of preventive actions that might be taken to address the increased 
risk of long-term morbidity and mortality is yet to be established. A 
major and focused research effort is required to address this issue.
3.3 | Exogenous influences on human male fertility
The reasons for the poor and apparently declining quality of semen 
from men in many populations remain elusive. A wide range of 
internal and external environmental variables potentially affects 
semen quality, both by effects on reproductive function of the 
mature adult and by effects on development of the male repro-
ductive system in utero. A number of male reproductive disorders, 
including poor spermatogenesis, testicular cancer, hypospadias, 
and cryptorchidism, have been found to be interrelated—both 
within individuals and at a population level. These factors, except 
isolated hypospadias, are associated with reduced fecundity. This 
has led to the proposal of a testicular dysgenesis syndrome (TDS) 
originating in fetal life.90 The potential for male reproductive func-
tion seems to be determined during a sensitive period in utero. This 
period has been identified in rodent models showing that normal 
development and later function of the male reproductive system 
are highly dependent on adequate androgen production during 
this sensitive window.122 It is likely that a similar sensitive period 
occurs in humans at around gestational weeks 8-14, termed ‘the 
masculinization programming window’. It has been suggested that, 
in humans, development can be disturbed by genetic defects, epi-
genetic factors, or adverse exposures, including maternal lifestyle, 
such as smoking during pregnancy, and exposure to environmental 
chemicals.93 Most likely, it is the cumulative effects of various low-
dose exposures in our environment, rather than single exposures 
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that contribute to the appearance of adverse effects in the male 
reproductive system. Animal studies provide evidence that man-
made chemicals can disrupt the hormone dependent pathways 
responsible for fetal gonadal development, subsequently leading 
to TDS-like symptoms.123-125 Causal relationships are inherently 
difficult to establish in humans. Although the maximum poten-
tial for adult semen quality seems to be determined in utero, ex-
posure to man-made chemicals in the environment and to other 
lifestyle-related stresses in the adult also influence semen quality. 
Additionally, several post-natal factors such as infections, surgical 
procedures, and medical treatment might cause reduced semen 
quality in adulthood.
A feature common to a number of these factors is excessive 
oxidative stress. Spermatozoa are known to generate reactive ox-
ygen species (ROS), which are believed to play an important role 
in normal sperm functions such as capacitation.126,127 However, 
spermatozoa are particularly vulnerable to high levels of oxidative 
stress, which damage sperm structure (including damage to DNA) 
and impair function.127-130 Excessive testicular levels of ROS are 
associated with varicocoele, infection, and inflammation131 but 
also with lifestyle-linked influences such as tobacco and alcohol 
usage and obesity. Suffice it to say, testicular function seems to 
be sensitive to adverse events both pre- and post-natally. Some of 
the potentially more significant environmental stresses are briefly 
considered below.
3.3.1 | Environmental and lifestyle factors
Environmental influences and stresses
Air pollution is ubiquitous, and the WHO estimates that ~90% of 
people breathe air containing high levels of pollutants (https ://www.
who.int/airpo lluti on/en/). Such pollution has been associated with a 
decrease in male fertility.132 Possible mechanisms include hormonal 
changes due to endocrine disruption (see below), oxidative stress, 
cell DNA alteration, or epigenetic modifications, probably function-
ing in combination. Simultaneous exposure to several pollutants im-
pedes identification of the impact of individual specific pollutants133 
and may result in synergistic interaction. Effects on regulation of 
scrotal temperature, for instance the consequences of sedentary 
occupations, might also be important. Application of scrotal heat 
stress in fertile men significantly decreased sperm concentration 
compared with pre-exposure values, as well as the percentages of 
motile and progressively motile spermatozoa and the proportion 
of morphologically normal spermatozoa. After removal of the heat 
stress, these parameters recovered to pre-exposure levels, the im-
pact apparently being reversible.134
Smoking
Although the mechanisms underlying the effects of tobacco smok-
ing remain uncertain, cigarette smoking is acknowledged to affect 
semen quality.116,135,136 Li et al,137 who undertook a large meta-
analysis from 26 countries/regions (20 studies, 5865 participants), 
concluded that smoking causes a decline in semen quality in both 
fertile and infertile men. Subgroup analyses indicated that effect 
size was higher in infertile men than in the general population and 
that deterioration of semen quality is ‘dose’-dependent, being 
more pronounced in moderate and heavy smokers (Sharma et al. 
2016). A recent systematic review (16 studies; 10 823 infertile 
male participants [5257 smokers and 5566 non-smokers]) reached 
similar conclusions.138 Oligozoospermia was significantly higher in 
smokers (RR: 1.29, 95% CI: 1.05-1.59), and normal sperm morphol-
ogy was significantly lower in smokers (morphological defect RR: 
2.44, 95% CI: 0.99-3.89). However, there was no apparent effect 
on motility.
Several cross-sectional studies show a significant effect of to-
bacco smoking on semen parameters and DNA fragmentation, as 
well as on gonadotrophin and testosterone levels.139-143 Paternal 
smoking also significantly negatively influences ART outcomes in-
cluding in IVF and ICSI.144 Among former smokers, every additional 
year following smoking cessation by the male partner reduced the 
risk of ART failure by 4%, particularly miscarriage.145 However, the 
data are not conclusive. For example, a prospective study on cou-
ples trying to conceive in the United States found little association 
between current male smoking or passive smoking in either part-
ner, with reduced fecundability.146 The Practice Committee of the 
ASRM, in their recent (2018) paper, concluded that ‘smoking has not 
yet conclusively been shown to affect male fertility’.147 Surprisingly, 
there are minimal data on the effect on semen parameters and fertil-
ity in men who have ceased smoking tobacco. Despite there being no 
absolute relationship between smoking tobacco and male infertility, 
available evidence supports a recommendation of smoking cessation 
and minimizing exposure to tobacco smoke among couples who are 
trying to conceive.
Electronic cigarettes (e-cigarettes) typically contain propylene 
glycol (a tasteless, odorless, colorless alcohol used in antifreeze), 
vegetable glycerin, a variable amount of nicotine, food grade fla-
voring, and water to generate an aerosol/vapor. Their use is com-
monly termed vaping and is generally viewed to be less harmful than 
conventional smoking. Nonetheless, studies in animal models show 
detrimental effects on spermatogenesis and increase in oxidative 
stress.148,149 Although large-scale human studies are not yet avail-
able, recent reports of severe pulmonary disease associated with the 
use of electronic cigarettes (vaping) has raised significant concern 
about their short- and long-term safety.150
Caffeine
A recent systematic review of 28 papers (19 967 men in total) showed 
that semen parameters were not adversely affected by caffeine in-
take from coffee, tea, and cocoa drinks in most studies. However, a 
negative effect of cola-containing beverages and caffeine-contain-
ing soft drinks on semen volume, count, and concentration was ob-
served. Caffeine intake appeared to be associated with aneuploidy 
and occurrence of DNA strand breaks. Coffee drinking in men was 
associated with prolonged time to pregnancy in some, but not all, 
studies.151
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Alcohol
Given that a significant number of men regularly drink alcohol, it is 
perhaps surprising that the impact of alcohol consumption on male 
fertility is not well understood. Overall, alcohol consumption has 
been associated with lower semen volume but has a variable, and 
probably dose-dependent, impact on semen parameters.137 Habitual 
alcohol consumption is associated with reduced semen quality and 
changes in reproductive hormones.152 Similarly, semen volume, 
sperm count, motility, and number of morphologically normal sper-
matozoa were all significantly decreased in a study of those with 
heavy and chronic alcohol consumption.153 In agreement with this, a 
recent meta-analysis indicates an effect of alcohol consumption on 
semen volume and sperm morphology. However, the review found 
no evidence for negative effects of occasional alcohol intake.154
Psychological stress
Psychological stress adversely affects testicular function such that 
stressful life events may be associated with decreased semen quality, 
an effect that might be primarily due to suppression of testosterone 
by raised corticosteroid levels.155 Gollenberg et al156 found that men 
reporting two or more recent stressful life events had an increased 
risk of having sperm concentration, motility, and morphology below 
‘normal’ WHO thresholds. A meta-analysis of 57 cross-sectional stud-
ies (29 914 participants) indicated that psychological stress could 
lower sperm concentration and progressive motility, and increase the 
fraction of abnormal spermatozoa.137 In a later cross-sectional study 
of 1215 Danish men, those with self-reported stress scores above an 
intermediate stress level had poorer semen quality and those with the 
highest stress levels had significantly lower sperm concentration, total 
sperm count, and seminal volume compared with those with interme-
diate stress levels.157 An association has also been reported between 
stress/depression and semen quality for those experiencing fertility 
issues.158 Antidepressant drugs used to treat depression, anxiety dis-
orders, chronic pain, and a variety of other conditions have negative 
effects on sexual function and semen quality.159 Nonetheless, non-
pharmacological management of stress for infertile men, including 
cognitive behavior therapy, psychotherapy, and fertility counseling 
and support, may be beneficial.160
Sleep
Sleep disturbance is common, and its prevalence is increasing.161 The 
influence of sleep (or sleep disturbance) on a range of physiological 
processes is well recognized and might contribute to male infertil-
ity.162,163 Testosterone secretion follows a diurnal pattern, with rise 
in testosterone levels coinciding with rapid eye movement (REM) 
sleep rather than with changes in levels of melatonin.164 Prolactin 
levels are also sleep-dependent, with an increase in prolactin se-
cretion during sleep. Sleep duration is associated with testis size in 
healthy young men,165 and obstructive sleep apnea, characterized 
by repetitive nocturnal hypoxia, is associated with increased levels 
of oxidative stress independent of obesity or reproductive hormone 
profile.166 Combined or interacting effects of stress, depression, and 
poor sleep on semen parameters may be significant.157,167-169
Dietary intake and obesity
Diet, both in terms of nutritional balance and (in combination with 
inadequate levels of activity) excessive calorific intake leading to 
obesity, affects semen quality and male fertility. Diets high in pro-
cessed meat, full-fat dairy products, alcohol, coffee, and sugar-
sweetened beverages are associated with poor semen quality and 
lower fecundity rates.170 Intake of full-fat dairy was inversely related 
to sperm motility and morphology among physically active men. 
Cheese, rather than overall dietary patterns, seemed to be primar-
ily responsible for this effect, but the mechanism linking dairy food 
intake to lower sperm motility and morphology was not clear.171 
However,162 reported lower sperm concentration and total sperm 
count were dose-dependently associated with high dietary intake of 
saturated fat among 701 young Danish men from the general popu-
lation. The authors expressed concern that changes in diet over the 
past decades might in part be responsible for the high frequency of 
subnormal sperm counts reported.
The current increase in the incidence of obesity is also of con-
cern with respect to male reproductive health. A meta-analysis of 
men from both the general population and from infertile couples 
showed the increased prevalence of azoospermia or oligozoosper-
mia in men who were overweight or obese.172 In a population-based 
prospective cohort of 501 couples, ejaculate volume showed an 
inverse linear relationship to body mass index and waist circum-
ference. Similarly, total sperm count showed a significant negative 
linear association with waist circumference. The authors concluded 
that ‘male infertility is a proxy of the overall male health status’.173 
Paternal obesity negatively affects both male fertility and assisted 
reproduction outcomes.174 A recent, large-scale study (4440 men) 
showed statistically significant relationships between obesity and 
semen analysis parameters.175 However, the effect of significant 
weight loss on semen analysis parameters is uncertain, and reports 
are conflicting, reporting either significant improvement,176-180 no 
change,181 or even deterioration.182,183 It is certainly worth noting 
that weight loss intervention is complex and is likely to underlie the 
heterogeneity reported in these studies. It is also difficult to know 
whether observed improvements in semen quality are related to 
weight loss per se or to other, confounding factors such as change in 
diet, increase in exercise, and improved metabolic profiles.
Endocrine disruptors and male fertility
Endocrine-disrupting chemicals (EDCs) are ‘exogenous substances, 
which have the ability to alter function(s) of the endocrine system 
and consequently cause adverse health effects in an intact organ-
ism, or its progeny, or (sub)populations’.184-186 Known EDCs are a 
diverse range of small, often lipophilic, molecules that fall within 
many different and widely used categories of chemicals, for exam-
ple, pesticides, pharmaceuticals, and plasticizers. Many of them are 
highly persistent and/or present at significant concentration in the 
environment such that humans are at high risk of exposure.187 Even 
those that are rapidly metabolized, such as phthalates and bisphenol 
A, can be present in human tissues at significant levels due to con-
tinuous exposure. Many EDCs have been shown to interfere with 
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the activity of sex hormone steroids and thereby might affect func-
tioning of the male reproductive system, for example, by acting as 
agonists or antagonists of the hormone receptors, by affecting the 
production or metabolism of endogenous sex steroids, or by modu-
lating hormone signaling events in other ways.
Toxicological studies on animals indicate that some EDCs may 
indeed impair the development and functioning of the male re-
productive system and thus might underlie, at least in part, the 
decline in human semen quality that has been observed in west-
ern populations (70,189; see Section 3.1). Sex differentiation of the 
male fetus seems to be particularly vulnerable to disruption of sex 
hormone function.90,93,190 However, attempts to establish an as-
sociation between levels of EDCs and semen quality in humans 
have proved difficult.191 Wang et al192 carried out a meta-analysis 
on association between EDC exposure and semen quality. Their 
analysis indicated that exposure to phthalates and organochlo-
rine insecticides, for example, dichlorodiphenyl trichloroethane 
[DDT] might be associated with reduced semen quality. These 
studies focused on associations between adult exposure and 
semen quality, while toxicological data indicate that fetal EDC ex-
posure, especially during sex differentiation, could have a lasting 
impact on adult reproductive function. Bonde et al193 undertook 
a large meta-analysis (33 papers, 28 study populations) and inves-
tigated association between pre-natal and perinatal EDC levels 
and four aspects of male reproductive function: cryptorchidism, 
hypospadias, low sperm counts, and testicular cancer. A signifi-
cant association of pre-natal and post-natal exposure to p,p′-DDE 
(p,p′-dichlorodiphenyldichloroethylene; a persistent metabolite of 
DDT) with the incidence of cryptorchidism, hypospadias, or testic-
ular cancer was detected (13 studies). However, the overall odds 
ratio for the analysis (all exposures and outcomes) was 1.11 (95% 
CI 0.91-1.35). Di Nisio & Foresta194 reviewed the data related to 
the effects of EDCs on male health and fertility, concentrating on 
phthalates, bisphenol A, organophosphate insecticides, perfluo-
roalkyls, and cadmium. They concluded that ‘Despite promising 
discoveries, a causal relationship between reproductive disor-
ders and exposure to specific toxicants has yet to be established.’ 
Bliatka et al,191 addressing the question of why clear evidence for 
the effects of EDCs on human male reproduction is still lacking, 
concluded that well-designed studies (case–control or cohort 
type) will be required. The timing of exposure in relation to rel-
evant sensitive periods of development also needs to be consid-
ered. Furthermore, toxicological data have shown that exposures 
to combinations of EDCs, even if their initial site/mode of action 
varies, have effects that are additive or synergistic.124,195 Simple 
dose–effect relationships of a single chemical may be masked by 
the concurrent exposure to other EDCs. Future studies should 
consider such combinations.
Anabolic-androgenic steroids
Anabolic-androgenic steroids (AAS) are non-prescription syn-
thetic testosterone-like substances misused by athletes and body-
builders.196 At least 30 different AAS exist, including testosterone 
and its precursors (androstenedione, dehydroepiandrosterone, 
DHEA), 17α-alkyl-derivates (oral preparations, such as stanozolol, 
oxandrolone, and methyltestosterone), and 17β-ester-derivates 
(parenteral preparations, including nandrolone and testosterone 
esters).197 They increase lean muscle mass in conjunction with 
weight training and are also used to improve strength and physi-
cal performance as well as exercise recovery. The vast majority of 
people who misuse steroids are male recreational power athletes 
in their 20s or 30s, with estimated 6.4% global lifetime prevalence 
rate.198
Simplistically, AAS use results in hypogonadotropic hypogonad-
ism, resulting in decreased secretion of endogenous testosterone as 
well as oligozoospermia or azoospermia and testicular atrophy.197 
The effects are usually reversible.199 However, it is notable that AAS 
users are more likely to take multiple supplements, including protein 
powders and creatine, other appearance- and performance-enhanc-
ing drugs (APED), and medication for erectile dysfunction 200 as well 
as recreational drugs.201
Lubricants
Although commonly available, studies have demonstrated most vag-
inal lubricants to be detrimental to spermatozoa in vitro.202-204 Their 
impact on fertility and natural conception is unclear at best,205 and 
however, the use of vaginal lubricants during intercourse should not 
be recommended for couples with infertility unless they are able to 
be deemed ‘Sperm safe’.206,207
3.3.2 | Occupational risks to male fertility
Effects of occupational exposure
The effects on male fertility of occupational risks are poorly ex-
plored in clinical, for example, NICE or strategic guidelines,1 yet 
there is a long history of research in this area. Most studies have ad-
dressed the question of occupational risk by examining semen qual-
ity as a surrogate marker of fertility of men in different occupations. 
Unfortunately, there is no consistency of assessment approach—for 
example, sperm concentration, motility, motile sperm concentration, 
and morphology have all been used as markers of fertility and data 
interpreted in different ways. There have also been studies examin-
ing the relationship between occupation and sperm DNA quality, but 
these are relatively rare and are similarly complicated by the array of 
different tests used (see section 2.3).
Occupational-related risks to fertility vary widely but can be 
simply classified into five types: physical agents (eg, noise, vibration, 
radiation, heat) and chemical agents (eg, fumes, gasses, aerosols, 
and mists); biological agents (eg, bacteria, fungi, insects, viruses); 
psychosocial (eg, stress, unsociable hours); Ergonomical (eg, man-
ual handling, repetitive movement, working in confined spaces). 
While there are no a priori hypotheses to link many of these risks 
to poor male fertility, most studies have only concentrated on the 
effects of chemical exposures. The landmark study, linking chemical 
exposure with male infertility, published more than 40 years ago, 
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was the identification of 1,2-dibromo-3-chloropropane (DBCP) ex-
posure as the cause of infertility in workers at a pesticide factory 
in California in 1977.209,210 However, progress in identifying other 
chemical risks to male fertility was slow and by the early 1980s only 
five chemical risks had been identified: carbon disulfide, inorganic 
lead, 1,2-dibromo-3-chloropropane (as above), ethylene dibromide 
(with DBCP), and toluene diamine.211 Subsequently, the risks of 
chemicals such as perchloroethylene, oxychlordane, and benzene 
were also identified.212
Perhaps the largest study to examine the relationship between 
occupation and semen quality was the Chemicals and Pregnancy 
Study (CHAPS-UK) which took place in the UK and examined the 
job history of nearly 2500 men attending 14 fertility clinics be-
tween 1999 and 2002. Analysis of the data from this study showed 
that: (a) moderate and high occupational exposure to glycol ether 
was related to low motile sperm count,213 (b) poor sperm morphol-
ogy was related to self-reported lifetime exposure to lead,214 and 
(c) self-reported use of paint stripper and lead, but not glycol ether, 
were significantly related to both low motile sperm count and poor 
sperm morphology.214 Interestingly, there was an increased risk 
of low motile sperm count215 but not poor morphology216 in men 
who were not working, suggesting a possible overall benefit to 
fertility of being in employment. While studies using measures of 
semen quality measures are relatively common, time to pregnancy 
(TTP) studies are rare. A meta-analysis of 23 studies suggested 
that TTP was increased following male partner exposure to lead 
and pesticides, with some evidence of harm following exposure 
to organic solvents or mixtures of oil products/chemicals.217 The 
overall consensus from studies seems to be that from a public 
health perspective, there are relatively few occupational risks to 
the fertility of adult men in Western (post-industrial) societies,218 
though this conclusion remains tentative as large, comprehensive, 
robust studies using multivariate models remains to completed. 
It is also very important to point out that, in comparison, little 
is known about the risks to adult men in low and middle income 
countries.
Mitigation of occupational risk
A hierarchy of control measures to mitigate occupational risks has 
been developed. These measures include hazard limitation (remove 
the hazard from the workplace), substitution (replace the hazard 
with an alternative procedure/substance that is believed to mitigate 
the risk), engineering (isolate workers from the hazard), administra-
tive (change working practices to minimize exposure), and Personal 
Protective Equipment (protect the worker by requiring that protec-
tive clothing or equipment is worn/used). There are relatively few 
documented examples of how these control measures have been 
used to mitigate occupational threats to male fertility. In the case of 
workers exposed to 1,2-dibromo-3-chloropropane (see above), while 
the first reports of effects on male fertility were published in 1977, 
it was not fully banned for agricultural use until 1985, and in 2009, 
it was still available in the supply chain. Advice to doctors about 
the clinical management of men working in high-risk occupations 
is generally poor. For example, National Institute for Health and 
Clinical Excellence advises that ‘some occupations involve exposure 
to hazards that can reduce male or female fertility and therefore a 
specific enquiry about occupation should be made to people who 
are concerned about their fertility and appropriate advice should be 
offered.’ However, there is no guidance about what the ‘appropriate 
advice’ should be.
4  | WORKSHOP SESSION 3— CLINIC AL 
MANAGEMENT OF MALE INFERTILIT Y
4.1 | Genetic and epigenetic aspects of male 
infertility
Male infertility is a multifactorial condition in which the occurrence 
of known genetic factors is relatively frequent (eg, Klinefelter syn-
drome). The clinical significance of identifying genetic factors re-
sponsible for male infertility is important in the era of IVF and more 
particularly ICSI. Patients affected by a severe male factor condition 
who were previously infertile can now generate their own biologi-
cal child. Counseling of the couple is an important requirement prior 
to IVF and in some instances includes testing of the female partner 
(for instance partner affected by congenital absence of vas deferens 
[CBAVD] due to cystic fibrosis transmembrane conductance regula-
tor [CFTR] mutations).
4.1.1 | Genetic testing
In azoospermic men, the risk of being a carrier of known genetic 
anomalies is high (20%-25%), with the frequency progressively de-
creasing with increasing sperm output.219-223 Genetic testing is 
therefore an essential tool for clinical decision-making. Identification 
of a causative genetic factor might allow prediction of outcome of 
testicular sperm retrieval, with the potential to avoid unnecessary 
surgical or medical treatments. It might also indicate the need for 
sperm cryopreservation in young adulthood if a progressive decrease 
in sperm production is predicted and/or highlight concerns regard-
ing the patient's general health. Routine molecular genetic testing in 
men with quantitative impairment of spermatogenesis is currently 
limited to karyotype analysis and azoospermia factor (AZF) dele-
tion screening. Chromosomal anomalies are the most frequent ge-
netic factors in severe oligo/azoospermia. These tests are indicated 
in all patients affected by moderate or severe oligozoospermia and 
azoospermia.220,224 Testing for AZF deletions has both diagnostic 
and prognostic value. Complete deletions of the AZFa and AZFb re-
gions cause azoospermia with virtually no chance of sperm recovery 
through testis biopsy. It is important to note that the definition of the 
extension of AZFb deletion with a specific set of markers is necessary 
for prognostic purposes. Moreover, AZF deletions will be transmitted 
to the male offspring so clearly informed, and appropriate counseling 
of the couple is vital.224
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4.1.2 | Mutation screening
Given the risk of transmitting genetic disorders, the diagnosis of 
known and the discovery of novel genetic factors in idiopathic infertil-
ity is of utmost clinical importance. Screening for mutations in can-
didate genes for specific male infertility phenotypes is not a routine 
practice but they are becoming increasingly available in a number of 
laboratories. Next-generation sequencing (NGS)-based panels are 
available for the following diseases: congenital hypogonadotropic hy-
pogonadism (cHH), partial or mild androgen insensitivity syndrome, 
CBAVD and monomorphic forms of teratozoospermia, and asthenozo-
ospermia.219,220,222,223 Genome-wide association studies (GWAS) are 
based on high-throughput analyses (single nucleotide polymorphism 
[SNP] arrays and array comparative genomic hybridization [a-CGH]). 
Use of GWAS has not added clinically relevant data to our knowledge, 
strongly suggesting that common or low-frequency polymorphisms 
do not have a major role from a diagnostic perspective.225 Only high-
resolution X chromosome-specific a-CGH studies were able to identify 
clinically relevant deletions, the TEX11 intragenic deletion, and CNV67 
(for reviews see219,220,226) Whole-exome sequencing has not proved 
to be a successful diagnostic tool in infertile patients with consan-
guineous parents or in familial cases of non-obstructive azoospermia 
(NOA), oligoasthenoteratozoospermia (OAT), monomorphic teratozoo-
spermia, or asthenozoospermia.219,220,227
4.1.3 | Epigenetic effects
In addition to the effects of genetic mutations, the importance of 
epigenetic factors in the determination of semen quality is now rec-
ognized. Epigenetic alterations such as unequal protamine ratios, aber-
rant DNA methylation, histone modifications, and miRNA profile have 
been described in association with decreased semen quality, decreased 
fertilization ability, DNA damage, and reduced IVF success and embryo 
quality.228 Aberrant methylation in imprinted genes could be responsi-
ble for imprinting diseases (Angelman and Beckwith–Wiedemann syn-
drome) in the offspring but this issue is still hotly debated. Diagnostic 
application of the acquired knowledge is still missing (methodological 
issues, lack of large studies,229 and the clinical significance of these ob-
servations is yet to be established. Notwithstanding this, there is, at 
least in the animal literature, a rapidly growing awareness of the impact 
of paternal epigenetic transmission to the next generation.230,231 The 
underlying mechanisms are still unclear, and the evidence in humans 
remains sparse, but this is an area of significant concern, and further 
research is clearly warranted.
4.1.4 | Future directions
Despite efforts and progress in understanding genetic defects un-
derlying male factor infertility, large proportions of NOA and OAT 
cases are still defined as idiopathic. Exome/genome analysis is prom-
ising but the diagnostic role of these approaches in infertile patients 
with unrelated parents (the majority are idiopathic sporadic NOA or 
OAT) is still under evaluation. A comprehensive collection of func-
tionally validated datasets and the development of new precise 
function predictor algorithms is needed to enable clinical interpre-
tation of the observed variants (especially heterozygous autosomal 
variants) identified in sporadic idiopathic cases of NOA or OAT. This 
can be achieved through data sharing via large international consor-
tia such as the GEMINI consortium (https ://gemini.conra dlab.org/) 
and the International Male Infertility Genomics Consortium (http://
www.imigc.org/).
An emerging clinical issue is the higher rate of morbidity (includ-
ing cancer) and lower life expectancy in infertile men (see section 
3.2). The significantly higher deletion load in infertile men com-
pared with normozoospermic men indicates a higher propensity to 
genomic instability in a subset of infertile men.219,226 Furthermore, 
defects in mismatch repair proteins may lead to both spermatogenic 
failure and predisposition to cancer development.232 This implies 
that infertile patients carrying specific genetic alterations need a 
lifelong follow-up to prevent or diagnose co-morbidities at an early 
stage (see above).
In addition to the effects of genetic mutations and epigenetic 
factors on male fertility, the role of gene–environmental interaction 
in male infertility is largely unexplored. Data on endocrine disrupters 
(see section 3.3.1 above) are still controversial, and the analysis of 
such an interaction has been performed mainly in animal models. 
The study of such effects in humans is highly challenging, but in the 
context of the apparent ongoing decline in semen quality (see sec-
tion 3.1.1 above), this must be urgently explored.
4.2 | Hormonal treatment of male infertility
Despite progress in diagnosing the causes of infertility, in many 
cases, the etiology remains unknown, termed ‘idiopathic infertil-
ity’.233 In this category of patients, a number of empirical treatments 
have been proposed, including hormonal therapies, with controver-
sial results.222,234
4.2.1 | Treatment of hypogonadotropic 
hypogonadism
Treatments for hypogonadotropic hypogonadism
Hypogonadotropic hypogonadism (HHG) is one of the few causes 
of male infertility where medical hormonal therapy is clearly effec-
tive. HHG is characterized by hypothalamic or pituitary dysfunction 
and low serum gonadotropin levels and reduced testicular function 
that presents clinically with testosterone deficiency, azoospermia, 
oligozoospermia, and/or small testicular volume. Clinical benefits 
have been reported for treatments with human chorionic gonado-
tropin (hCG) alone or in combination with urinary follicle-stimulating 
hormone (FSH235,236) Pulsatile gonadotropin-releasing hormone 
(GnRH) therapy seems to be the most physiological approach for 
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replacing hormones in HHG but, since it acts by inducing release of 
gonadotropic hormones from the anterior pituitary, it is a rational 
choice only for subjects with normal pituitary function.237-239 Both 
pulsatile infusion of GnRH and combined gonadotropin and human 
menopausal gonadotropin (hCG/hMG) can effectively induce sper-
matogenesis in men with HHG, although it is not known which treat-
ment regimen might be best.240 Recombinant hCG236 and LH241 are 
also available, but their efficacy remains unknown. GnRH therapy 
is reported to induce a pregnancy rate of up to 80%, with a time 
to achieve pregnancy similar to combined gonadotropin therapy.242 
Worldwide, GnRH is less likely to be used than hCG alone or in com-
bination with FSH due to cost, inconvenience and ineffectiveness in 
cases of panhypopituitarism or GnRH receptor mutation. A recent 
retrospective study240 found that pulsatile GnRH therapy was as-
sociated with earlier spermatogenesis and larger testicular size com-
pared with combined gonadotropin therapy. However, prospective 
randomized studies are required.
Use of FSH pre-treatment
The most important determinant of a successful response to gon-
adotropin therapy is baseline testis volume, higher volume being 
associated with a faster achievement of spermatogenesis.242,243 
The optimal regimen in patients with severe cases (testicular vol-
ume < 4 ml) is unknown. Fertility outcome is generally poorer in pa-
tients with signs of absent mini-puberty.236,238 Pre-treatment with 
recombinant FSH prior to GnRH therapy (to mimic mini-puberty) 
may improve fertility outcomes and can be considered as an alter-
native to GnRH alone.244 Data from animal studies indicate that a 
pre-pubertal ‘window’ occurs in the immature testis during which 
FSH can induce Sertoli cell proliferation.245 Although use of FSH 
pre-treatment did increase sperm count and rate of conception com-
pared with treatment with GnRH alone, the difference did not reach 
statistical significance and larger prospective studies are needed.
Recombinant human FSH (rhFSH) preparations seem to be as ef-
ficacious as the urinary derivatives,233 with no difference in terms of 
stimulation of spermatogenesis or sperm concentration.246 For bet-
ter compliance, long-acting FSH formulations have been proposed 
(ie, corifollitropin alfa) in place of rhFSH,247 which may improve pa-
tient satisfaction and compliance. Results have been encouraging, 
suggesting that, for men suffering from HHG who desire fertility, 
long-acting corifollitropin alfa can effectively and safely replace 
rhFSH in the treatment regimen. However, additional studies are 
needed. Comparative studies of different FSH preparations in males 
have not yet been thoroughly conducted. Moreover, there are no 
randomized controlled studies comparing gonadotropin treatment 
regimens.246 The low prevalence of idiopathic HHG and other 
forms of HHG presents a significant obstacle to the organization of 
such trials and placebo-controlled studies, resulting in the absence 
of pubertal development in the control group, would be ethically 
unjustifiable.
After completion of therapy for infertility, most men with 
HHG will benefit from lifelong hormonal therapy.248 This is usually 
achieved by switching to testosterone replacement. This will result 
in a return to clinical infertility, but it is more cost-effective than go-
nadotropin replacement therapy, and its use for long durations has 
been better characterized.249 The best therapeutic choice needs to 
be elucidated for these vulnerable patients.
4.2.2 | Hormonal treatment of idiopathic infertility
The use of empirical medical therapies remains inconclusive and 
disappointing for men with idiopathic infertility. Estrogen receptor 
antagonists (eg, Tamoxifen, clomiphene) may be applied on the basis 
that a non-invasive treatment with limited side effects can be ef-
fective.250 Aromatase inhibitors have also been recommended for 
men with impaired sperm parameters and a low testosterone/estro-
gen ratio but the data are limited.251 RhFSH or purified human FSH 
application to idiopathic male infertility is more controversial.250 
Further evidence for the efficacy of and selection criteria for medi-
cal treatment of oligoasthenoteratozoospermia (OAT) is required.250 
The lack of clear consensus on the management of these conditions 
reflects our poor understanding of underlying etiology.
Finally, impaired semen quality may be associated with hypogo-
nadism.250 Treatment with exogenous testosterone is sometimes 
given but is not appropriate. Typical therapeutic doses of testoster-
one act as negative feedback on the hypothalamic–pituitary–gonadal 
axis, inhibiting secretion of LH and greatly reducing endogenous tes-
tosterone production.207,250 If hypogonadism coincides with fertility 
issues, hCG treatment, which stimulates testosterone production of 
Leydig cells, could be considered, especially in men with low gonad-
otropins (secondary hypogonadism).
4.3 | Non-hormonal medical treatment of male 
infertility
In addition to the hormonal approaches outlined above, non-
hormonal treatments have a role in clinical management of male 
infertility. Such treatments may effectively remove a revers-
ible cause of infertility or can result in sufficient amelioration of 
the environment in which spermatozoa are produced and ma-
ture, that semen parameters are significantly improved. In cases 
such as idiopathic OAT or infertile patients without identifiable 
cause(s), non-hormonal treatments are frequently used, such as 
anti-inflammatory drugs and treatment with or enrichment of di-
etary antioxidant compounds and vitamins. Currently, the scien-
tific evidence for the effectiveness of such empirical treatment 
is relatively poor and further studies are required to clarify the 
role of this approach.252,253 However, three characterized, often 
co-existing conditions that interfere with reproductive function 
(oxidative stress, inflammation, and infection) may be responsive 
to focused (non-empirical) non-hormonal treatments.254 These 
are the use of antioxidants (to ameliorate the damaging effects of 
excessive oxidative stress) and treatment with anti-inflammatory 
and antibiotic drugs.
     |  15CONSENSUS WORKSHOP GROUP
4.3.1 | Antioxidants
There is a significant body of evidence to support the role of oxi-
dative stress in sperm dysfunction,126 and thus, antioxidant ther-
apy appears a logical approach. A plethora of different products 
has been used clinically, and there are many, readily available, pu-
tative fertility-enhancing supplements on the market. However, 
critical evidence to support their use is absent (Martins da Silva 
2019).255
A systematic review and meta-analysis of effect of nutrients 
and dietary supplements256 found that sperm concentration was 
increased by selenium, zinc, omega-3 fatty acids, and coenzyme 
Q10 (CoQ10). Sperm counts were increased by omega-3 and CoQ10 
supplementation. Selenium, zinc, omega-3, CoQ10, and carnitines 
increased sperm total motility, whereas sperm progressive motility 
was increased only after supplementation with carnitines. Finally, 
sperm morphology was enhanced by selenium, omega-3, CoQ10, 
and carnitine supplementation. Importantly, however male fertility 
was not assessed and the authors conclude that the results should 
be interpreted cautiously due to the limited sample size of the 
meta-analyzed studies and the considerable observed interstudy 
heterogeneity.256
A recent Cochrane review, which examined the role of supple-
mentary oral antioxidants in subfertile men,253 concluded that there 
was an increased live birth rate associated with antioxidant use for 
male subfertility (OR 1.79, 95% CI 1.20–2.67). However, the data 
were limited, being based on 7 randomized clinical trials, compris-
ing 750 men and only 124 live births. A further 11 trials (786 men) 
indicate that antioxidants may increase clinical pregnancy rate (OR 
2.97, 95% CI 1.91–4.63). However, when studies at significant risk 
of bias were removed from the analysis, there was no evidence of 
increased live birth rate. Overall, the evidence from these trials is 
low quality and the authors conclude that the data are inconclusive. 
While a healthy diet is certainly conducive to a healthy body and 
hence a potential association with gamete quality, we are a long way 
from concluding that supplementation of the diet is clearly benefi-
cial for male fertility. Large randomized placebo-controlled trials are 
required to address these questions.255
4.3.2 | Anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs (NSAID) may have an impact 
on semen parameters. Some studies reported deleterious effect of 
salicylates and profens257-259 on semen parameters. On the other 
hand, data on the effect of cox-2 inhibitors and sulfonanilides indi-
cate positive effects.260,261 Overall, it appears that, though NSAIDs 
might be useful for relief of symptoms in treating acute forms of 
male accessory gland inflammation, they should (if possible) be 
avoided for chronic usage. More studies are required to examine 
the positive effects of cox inhibitors on patients with ‘idiopathic’ 
leukocytospermia.254
Steroidal anti-inflammatory drugs
Steroidal anti-inflammatory drugs, such as glucocorticoids, have 
been used for the treatment of men with antisperm antibodies (ASA) 
but the results from RCTs have been mixed. Three showed no signifi-
cant difference in pregnancy rates.262-264 Two other RCTs showed 
a significant increase in pregnancy rate,265,266 and a more recent 
RCT267 on 241 men found that prednisolone treatment improved 
sperm motility/progressive motility and pregnancy rate in IVF (but 
not ICSI). However, before use, it is important to establish potential 
side effects of these treatments.
4.3.3 | Antibiotics
Where sub/infertility is associated with a clear bacterial infection 
(male accessory gland infection (MAGI), the use of antibiotics in 
treatment is well established. The choice of antibiotic prescribed 
is based up the nature of the microorganism identified (see 
review254).
Use of antibiotic treatment in men with leukocytospermia is 
much more contentious, particularly given global concerns of an-
timicrobial resistance (https ://www.who.int/antim icrob ial-resis 
tance/ global-action-plan/en/). A systematic review268 identified 
only 11 RCTs concerning treatment of leukocytospermia performed 
over two decades (1984-2003).t The studies used variable meth-
odology for leukocyte assessment and dose/duration of antibiotic 
intervention (quinolones, tetracyclines, macrolides, sulfonamides, 
and penicillins). Three of the trials showed statistically significant 
improvement of sperm concentration and/or motility between the 
treated and untreated groups,269-271 but in three other studies no 
statistically significant differences were reported.272-274 One trial 
reported significant improvement of sperm motility and morphol-
ogy.275 Antibiotics resulted in a statistically significant resolution 
of leukocytospermia in 5/8 trials.270,271,276,277 The cure rate was 
reported in only 3/11 trials270,271,273 but all studies showed a 
statistically significant decrease in the number of seminal bacte-
ria. Four of the studies270,271,276,277 reported the pregnancy rate 
after treatment but only one271 showed a statistically significant 
improvement in the treated group compared with the untreated 
group. Overall, number of pregnancies was higher in the treatment 
groups. A complication for the use of antibiotics in treatment of 
male fertility is that there is evidence for adverse effects of an-
timicrobials on testis and sperm function. In summary, there are 
limited data available and there is a ‘substantial need for well-de-
signed clinical trials in this area’.278-280
5  | WORKSHOP SESSION 4—THE OVERUSE 
OF IC SI
There is absolutely no question that ICSI treatment for male fac-
tor infertility has transformed reproductive medicine and offers a 
clear option for treatment. However, there has been a significant 
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trend to use ICSI for non-male factor cases. For example, accord-
ing to data from US National Assisted Technology Surveillance 
system (1996-2012), 65% of fresh cycles used ICSI yet only ~36% 
were reported male factor infertility.281 Hans Evers highlighted the 
overuse of ICSI in a specific editorial entitled ‘Santa Claus in the 
fertility clinic’.282 Data from ICMART (International Committee for 
Monitoring Assisted Reproductive Technologies,283 showed a sub-
stantial difference in the ICSI:IVF ratio from 1.4 in Asia to 60.3 in 
the Middle East. A recent ICMART report5 using data from sixty-five 
countries and 2560 ART clinics showed that ‘large disparities exist 
with ICSI used in nearly 97% of Middle East cycles compared with 
55% in Asia and 69% in Europe’. The first report of ART in Africa6 
documented that 89% of aspirations were using ICSI (19,207/21,238 
aspirations). According to the CDC, for women under 35 years of 
age, the majority of fresh, non-donor retrievals (68.9%) which used 
ICSI were ‘without male factor’.284 Clearly, ICSI use for non-male 
factor is widespread.
The justifications for the use of ICSI in non-male factor cases, 
for example, advanced maternal age, potential failed fertilization, 
unexplained infertility, cycles with few oocytes, and the counterar-
guments are well rehearsed.282,285 However, it is important to rec-
ognize that the overwhelming majority of published data show no 
clinical benefit for ICSI use in non-male factor cases. For example, 
Li and colleagues examined a population-based cohort of 14 693 
women in Victoria, Australia, between July 2009 and June 2014. 
They concluded that ICSI resulted in similar cumulative live birth 
rate compared with IVF for couples with non-male factor infertil-
ity.286 More recently, Sustar et al287 analyzed 3363 stimulated cycles 
(IVF = 1661, ICSI = 1702) and concluded that use of ICSI in normo-
zoospermic men may result in lower clinical pregnancy and live birth 
rates.
Irrespective of this, there are key questions, as yet unan-
swered, that need to be addressed to minimize unnecessary treat-
ment while maximizing success. Firstly, how do we appropriately 
select men with male factor infertility? Traditionally, male factor 
infertility has been diagnosed using basic semen parameters and 
the limitations of this approach are outlined above (section 2.1). 
To date, we have little data on more appropriate methods to diag-
nose the male (see section 2.2) and this makes the identification of 
those cases that are most suitable for ICSI very challenging and of 
course is a key argument used to justify ICSI for all. Nevertheless, 
it is critical we develop tools to diagnose the male in a more ro-
bust manner so that appropriate rational therapy can be applied. 
Furthermore, even when ICSI might be deemed appropriate, de-
spite decades of research, we still have little idea how to select the 
best spermatozoon for injection.52,288 Secondly, what are the long-
term consequences of ICSI treatment? Even though initial data are 
relatively reassuring,289,290 there is an urgent need, as expressed 
by the WHO Evidence Synthesis Group, to examine the long-term 
health outcomes of the children born from men with compromised 
fertility whatever the nature of the compromising event(s) (eg, ge-
netics, environmental, iatrogenic, and/or occupational).1 Moreover, 
when ICSI is used even though there is not a male factor issue, a 
fundamental question remains: Are there are any additional risks 
from the procedure itself285,291?
6  | DISCUSSION
The consensus group discussed the issue of semen analysis at length. 
It was agreed that basic semen analysis provides diagnostic but lit-
tle functional information and that progress in assessment of sperm 
function over the last 25 years has been very limited and disappoint-
ing. Areas of major concern were the persistence of large variation 
between laboratories in the quality of semen analysis (including 
poor technical standards and failure to comply with WHO guide-
lines) and inconsistencies and confusion regarding interpretation of 
the data. The question of failure to follow WHO guidelines suggests 
that training and quality control measures are not effective. There 
is a real and immediate need to address this problem at national and 
international levels. Possibilities discussed included a regulatory re-
quirement for trained andrologist in every clinic (which is already the 
case in some countries) and incorporating semen analysis standards 
into laboratory inspection and training. There was also an extended 
discussion about the use of WHO semen analysis reference ranges 
as cut-offs and the urgent need to accept and to explain to patients 
that semen analysis allows estimation of probability of successful 
conception/IVF fertilization but is very often not a yes/no diagnosis.
The discussion of functional tests mostly concerned the useful-
ness of those already available. Should tests of DNA fragmentation 
be used only in specific circumstances, for example patients who 
have had chemotherapy? Should such tests be used at all since there 
is no corrective treatment available? Some members of the group 
felt that patients wanted to know what was wrong—whereas oth-
ers reported that patients attending their clinic just want a healthy 
child. As with semen analysis, there is interlaboratory variation in 
testing and there might be benefit in having regional, specialized 
testing centers. There was universal agreement that development of 
simple, cost-effective functional tests should continue to be an ob-
jective for researchers and industry, particularly aiming for accuracy 
and ease of use through automation. Furthermore, since most tests 
are destructive (providing information about the sample population 
but not about the actual cell(s) tested), development of non-destruc-
tive tests that provide information on the status of an individual cell 
would be extremely valuable.
There was acceptance that the evidence for a progressive fall in 
human sperm counts was becoming much stronger and that there 
was a need for further research, both to widen the range of popu-
lations investigated (nearly all data currently concern western men) 
and to resolve doubts regarding the nature of the observed trend. 
In particular, prospective studies should be carried out. Another 
significant point raised in discussion was that the data suggest that 
birth year is more important than year of testing, suggesting that 
the factors responsible for the observed decline might exert major 
effects on development of testicular capacity in utero. A number of 
issues discussed related to both environmental/lifestyle influences 
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and occupational exposure, including the importance of realizing 
that exposures are often to mixtures of chemicals/toxicants and that 
significant interactions and synergistic effects might occur. Also, the 
effects of exposures to these compounds must be considered within 
their genetic background, both when developing hypotheses and 
designing studies, which will require global collaboration. Another 
area of significant discussion was the need for balanced communica-
tion of concerns to governments and to the public—which requires 
use of the ‘collaborative engagement’ model. Surprisingly, there are 
very few examples of a coordinated approach to male reproduc-
tive health. The best example is that of, ‘Healthy Male’ (formerly 
Andrology Australia https ://www.healt hymale.org.au/) coordinated 
by the Australian Government. Unfortunately, other governments/
national societies have not followed this comprehensive approach.
A key factor identified during the discussion was the lack of a 
quantitative, detailed assessment of the economic, and societal 
burden of male reproductive health. For almost all other diseases, 
compelling evidence of economic effect has been presented, but no 
such analysis has been undertaken for male reproductive health.2 
An accurate economic impact assessment is fundamental to under-
pin scientific arguments and modify policy. A good example of such 
analysis is that of weather forecasting. Alley and colleagues argued 
that investment in accurate weather prediction models paid eco-
nomic dividends ranging from 3 to 10 times the amount invested.292 
The World Bank report on funding of weather forecasting suggested 
that meeting a worldwide investment need of 1.5-2 US$ billion and 
ongoing annual costs of ~500 million could save 23 000 lives per 
year and would achieve up to US$ 30 billion per year in economic 
benefits.292 These are powerful statements that help highlight the 
impact of a discipline to policymakers.
The consensus group agreed that advice about the effects of life 
exposures on fertility had value but also felt that, although there was 
clear evidence for effects of lifestyle/behavior prior to attempting 
to conceive, the evidence for improvement after intervention, for 
example giving up smoking was poor. More detailed and powerful 
studies on such interventions are needed. Similarly, it was felt that 
more evidence is needed to guide the use of therapies such as anti-
oxidants for the reduction of oxidative stress. Could there be a sub-
population that would benefit from such therapy (potentially related 
to genetic background) and might there even be a subpopulation for 
whom free radical levels were already unusually low such that they 
should not be further lowered? Development of robust routine test-
ing of semen for free radicals/oxidative stress is needed.
A fundamental point that was raised in many of the presentations 
and throughout the discussion was the need, in almost all areas, for 
large, high-quality robust studies, including well-controlled RCTs.
Following presentation of evidence, debate and discussion the 
group identified a series of 36 consensus points. One important ob-
jective of providing these is for them to provide clear statements 
of evidence gaps and/or potential future research areas/topics. 
Appropriate funding streams addressing these can then be priori-
tized, and consequently, in the short and medium term, answers 
can be provided. By using this strategic approach, our discipline can 
make the rapid progress necessary to address key scientific, clinical, 
and societal questions that do and will face us.
7  | CONSENSUS POINTS
1. Male subfertility is a complex and heterogeneous condition. The 
development of robust diagnostics and treatment interventions 
should ultimately allow development of individualized approaches 
to patient care.
2. A detailed economic impact assessment of the costs of male sub-
fertility and infertility is urgently needed.
3. There is a need for prospective collection of quality semen analy-
sis data from global sources to improve clinical and health policy 
decision-making.
4. Threshold values for semen analysis have an acceptable specific-
ity but low sensitivity for identifying male (sub)fertility. Therefore, 
caution should be used in the interpretation of results in relation 
to the WHO manual reference values.
5. Semen quality is not just a matter of reproductive potential. 
There is an emerging clinical issue related to the higher morbid-
ity (including cancer) and lower life expectancy in subfertile men 
relative to the general population. Recent studies have revealed 
genetic links in some cases. The identification of co-morbidities 
needs to be the subject of prospective studies.
6. Interpretation of semen analysis results will be guided by the end-
point of interest.
7. Interpretation of semen analysis for diagnosis of male subfertility 
is more predictive when several semen characteristics are consid-
ered together.
8. There is a clear need for training and education, at the national 
and international level, of laboratory personnel performing semen 
analysis, leading to individual certification. This requires effective 
maintenance of competence, internal quality control, and external 
quality assurance programs.
9. There is a need to develop accurate, automated methods for 
semen analysis and testing sperm functional potential. This could 
include development of point-of-care devices that have been fully 
validated and include accompanying QC/QA tools.
10.  Definitions of the specific quality expectations and performance 
of QC/QA programs in laboratory andrology are needed.
11.  At present, most sperm function tests are too technically com-
plex and/or expensive for routine use. Simpler, robust, cost-
effective tests are needed, with validated, prospective clinical 
endpoint data to support the interpretation of results.
12.  Sperm DNA fragmentation is higher in some men with subfertil-
ity. However, the range of tests and variations in protocols, as 
well as a general lack of test-specific validated threshold values, 
continues to limit its potential clinical utility. Large-scale, pro-
spective clinical studies are needed.
13.  Research efforts should be focused on the development of non-
destructive tests of sperm function that allow the tested sperm 
to be selected and used in the attempt to establish a pregnancy.
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14.  The studies that show a decline in sperm count raise concerns 
with regard to future male fertility and health. However, they 
are potentially influenced by the assessment methods that were 
used. Therefore, prospective studies using rigorously standard-
ized methodology are warranted.
15.  These prospective studies should take into account that the birth 
year is likely to have more influence on the result than the year 
in which the test was performed. This is because it is likely that 
in utero exposures influence testicular functional capacity that 
can then be further affected by personal and environmental 
exposures.
16.  Male reproductive health studies that take into account the in-
teraction between environmental exposures and genetic back-
ground should be conducted.
17.  High-quality epidemiological studies in diverse populations are 
needed to better identify environmental and occupational risks 
to male reproductive health.
18.  Mixtures of chemicals and additional exposures should be taken 
into consideration when studying their effect(s) on male repro-
ductive health. Caution is urged in relation to studies of individ-
ual chemicals or single exposures.
19.  Pharmaceutical reference sources need to include more informa-
tion on potential adverse effects on male reproductive health.
20.  There is a need to develop effective methods and engagement 
strategies to provide information about male reproductive health 
to the public, regulators, and policymakers.
21.  There are few effective medical interventions for male infertil-
ity. Hypogonadotropic hypogonadism is a well-defined condition 
that responds to hormonal treatment.
22.  In general, there is no good quality evidence to support empiri-
cal hormonal treatment for idiopathic oligozoospermia or un-
explained male subfertility. Large-scale studies are needed to 
identify who could benefit from this type of treatment; a clinical 
endpoint of such studies should be live birth rate.
23.  Exogenous testosterone treatment should not be used in an at-
tempt to improve sperm production as it has a negative effect on 
spermatogenesis.
24.  Since medical professional societies have already addressed the 
controversial topic of varicocoele treatment, the group elected 
not to consider it further.
25.  TESE and micro-TESE are ways of obtaining spermatozoa in 
some, but not all men with non-obstructive azoospermia. Only 
a few markers are known to predict poor TESE outcome (eg, 
Y-chromosome microdeletions), and therefore, additional mark-
ers are needed to identify those who would benefit from this 
procedure.
26.  A better understanding of the etiology of spermatogenic arrest is 
needed to identify and develop treatments for affected men.
27.  Future research should focus on finding simple, cost-effective 
screening technologies for male genital tract infection.
28.  Smoking negatively affects personal and reproductive health. 
Patients should be offered smoking cessation strategies to mini-
mize exposure to tobacco smoke and vaping.
29.  Oxidative stress is a recognized pathology in male subfertility. 
Dietary and vitamin supplements appear to improve semen qual-
ity, but the data are unclear as to whether antioxidant supple-
mentation is an effective intervention. Further, well-designed, 
large-scale randomized controlled trials are needed.
30.  The use of intimate lubricants should be recommended with cau-
tion since many are toxic to sperm. If a coital lubricant is needed, 
products established as being ‘sperm friendly’ should be used.
31.  Genetic testing in azoospermia, severe oligozoospermia, total 
lack of sperm motility, and monomorphic teratozoospermia has 
diagnostic and prognostic value and is important for genetic 
counseling.
32.  With the current diagnostic tests, there is still a large proportion 
of idiopathic NOA/OAT cases who are likely to be affected by 
undefined genetic factors. Exome/genome analysis studies have 
the potential to develop a gene panel to enhance diagnosis and 
pre-TESE prognosis in such men.
33.  The current data do not support the use of ICSI for non-male fac-
tor patients.
34.  Not all cases of male factor infertility justify treatment by ICSI; 
some could be treated using IUI or IVF.
35.  The potential risks of the indiscriminate use of ICSI to the health 
of children have yet to be firmly established. High-quality longi-
tudinal studies are therefore required.
36.  Given concerns related to the indiscriminate use of ICSI, more 
research is required to better understand the sperm's contribu-
tion to fertilization and early embryonic development.
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